AcuCort AB (ACUC.ST) Research

Specializing in pharmaceutical innovation, AcuCort AB (publ) focuses on the development and commercialization of glucocorticoid dexamethasone film products, particularly for acute allergic conditions. Among its offerings is Zeqmelit, a medication with diverse therapeutic uses. Zeqmelit addresses severe and acute allergic reactions, pediatric croup, chemotherapy-induced nausea and vomiting, and also serves as a treatment for COVID-19 patients who require supplemental oxygen. The company, established in 2006, is headquartered in Lund, Sweden.

Market snapshot

Symbol
ACUC.ST
Price
$0.45
Day change
-32.69%
Market cap
$105.7M
P/E ratio
-3.22x
52-week range
0.401-0.95
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Alzinova AB (publ) (ALZ.ST)
  • BrainCool AB (publ) (BRAIN.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • Klaria Pharma Holding AB (publ.) (KLAR.ST)
  • Neola Medical AB (publ) (NEOLA.ST)
  • Nanologica AB (publ) (NICA.ST)
  • Q-linea AB (publ) (QLINEA.ST)
  • SciBase Holding AB (publ) (SCIB.ST)

Open AcuCort AB (ACUC.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.